12:00 AM
 | 
Oct 26, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Fampridine-SR regulatory update

Acorda said FDA extended the PDUFA date for an NDA for Fampridine-SR to improve walking ability in patients with multiple sclerosis by three months to Jan. 22 from Oct. 22. Acorda said it...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >